203 related articles for article (PubMed ID: 34405836)
1. Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review.
Brown AM; Masterson W; Lo J; Patel AB
Dermatitis; 2023; 34(3):201-208. PubMed ID: 34405836
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
3. Treatment Outcomes of Immune-Related Cutaneous Adverse Events.
Phillips GS; Wu J; Hellmann MD; Postow MA; Rizvi NA; Freites-Martinez A; Chan D; Dusza S; Motzer RJ; Rosenberg JE; Callahan MK; Chapman PB; Geskin L; Lopez AT; Reed VA; Fabbrocini G; Annunziata MC; Kukoyi O; Pabani A; Yang CH; Chung WH; Markova A; Lacouture ME
J Clin Oncol; 2019 Oct; 37(30):2746-2758. PubMed ID: 31216228
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
6. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
7. Mucocutaneous adverse events to immune checkpoint inhibitors.
Muhaj F; Karri PV; Moody W; Brown A; Patel AB
Front Allergy; 2023; 4():1147513. PubMed ID: 36938327
[TBL] [Abstract][Full Text] [Related]
8. Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.
Hsieh CY; Tsai TF
Am J Clin Dermatol; 2022 Nov; 23(6):869-879. PubMed ID: 35964277
[TBL] [Abstract][Full Text] [Related]
9. Management of bullous pemphigoid: recommendations for immunomodulatory treatments.
Kirtschig G; Khumalo NP
Am J Clin Dermatol; 2004; 5(5):319-26. PubMed ID: 15554733
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
Front Immunol; 2020; 11():588582. PubMed ID: 33708189
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid.
Shi CR; Otto TS; Thompson LL; Chang MS; Reynolds KL; Chen ST
Eur J Cancer; 2021 Dec; 159():34-37. PubMed ID: 34731747
[No Abstract] [Full Text] [Related]
12. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
Barrios DM; Phillips GS; Geisler AN; Trelles SR; Markova A; Noor SJ; Quigley EA; Haliasos HC; Moy AP; Schram AM; Bromberg J; Funt SA; Voss MH; Drilon A; Hellmann MD; Comen EA; Narala S; Patel AB; Wetzel M; Jung JY; Leung DYM; Lacouture ME
Ann Oncol; 2021 Jun; 32(6):736-745. PubMed ID: 33667669
[TBL] [Abstract][Full Text] [Related]
13. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM
An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
Pach J; Leventhal JS
Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
[TBL] [Abstract][Full Text] [Related]
15. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.
Lacouture ME; Goleva E; Shah N; Rotemberg V; Kraehenbuehl L; Ketosugbo KF; Merghoub T; Maier T; Bang A; Gu S; Salvador T; Moy AP; Lyubchenko T; Xiao O; Hall CF; Berdyshev E; Crooks J; Weight R; Kern JA; Leung DYM
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38652814
[TBL] [Abstract][Full Text] [Related]
16. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid.
Kwon IJ; Kim T; Yoo DS; Min S; Kim SC; Kim JH
J Dermatol; 2023 May; 50(5):705-709. PubMed ID: 36514846
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
Morris LM; Lewis HA; Cornelius LA; Chen DY; Rosman IS
J Cutan Pathol; 2020 Aug; 47(8):742-746. PubMed ID: 32196722
[TBL] [Abstract][Full Text] [Related]
18. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
19. [Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].
Gomes N; Sibaud V; Azevedo F; Magina S
Acta Med Port; 2020 May; 33(5):335-343. PubMed ID: 32416756
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based management of bullous pemphigoid.
Daniel BS; Borradori L; Hall RP; Murrell DF
Dermatol Clin; 2011 Oct; 29(4):613-20. PubMed ID: 21925006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
